DNA methylation in schizophrenia subjects: Gender and MTHFR 677C/T genotype differences

Epigenomics

Volumn 4, Issue 3, 2012, Pages 261-268

  Burghardt, Kyle J ^a   Pilsner, J Richard ^b   Bly, Michael J ^a   Ellingrod, Vicki L ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

females; folate; metabolic syndrome; methylation; MTHFR; schizophrenia

Indexed keywords

FOLIC ACID;

ADULT; AGED; ARTICLE; COMT GENE; DIET SUPPLEMENTATION; DIETARY INTAKE; DNA DETERMINATION; DNA METHYLATION; FEMALE; FOLIC ACID BLOOD LEVEL; GENDER; GENE; GENOTYPE; HUMAN; INCIDENCE; LABORATORY TEST; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MTHFR GENE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; METABOLIC SYNDROME X; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MOLECULAR TYPING; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEX FACTORS;

EID: 84862244727     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.25     Document Type: Article

References (30)

1. Roffman JL, Nitenson AZ, Agam Y et al. A hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS ONE 6(9), e25253 (2011).
2. Roffman JL, Gollub RL, Calhoun VD et al. MTHFR 677C --< T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --< Met. Proc. Natl Acad. Sci. USA 105(45), 17573-17578 (2008). First study to examine the relationship between variants related to folic acid metabolism and schizophrenia with regard to the illness psychopathology. This work has been subsequently followed up by these authors.
3. Ellingrod VL, Taylor SF, Dalack G et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J. Clin. Psychopharmacol. 32(2), 261-265 (2012).
4. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr. Res. 98(1-3), 47-54 (2008). First study to examine the pharmacogenetics of folic acid in relation to metabolic syndrome in schizophrenia subjects. These authors have subsequently followed this work with a confirmatory study.
5. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr. Res. 121(1-3), 193-198 (2010).
6. Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv. Rev. Psychiatry 15(4), 146-160 (2007). A comprehensive review of folic acid, its role within the Aldo Met cycle, and its relationship with both schizophrenia and depression.
7. Chen J, Lipska BK, Halim N et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75(5), 807-821 (2004).
8. Roffman JL, Weiss AP, Deckersbach T et al. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(6), 990-995 (2008).
9. Roffman JL, Weiss AP, Purcell S et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol. Psychiatry 63(1), 42-48 (2008).
10. Roffman JL, Weiss AP, Deckersbach T et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr. Res. 92(1-3), 181-188 (2007).
11. Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis. 3(2), A42 (2006). The authors compared the standardized mortality rates between patients with serious mental illness and the general population. Although they found differences related to mortality that was related to geographics, they did show that the majority of years lost attributed to mental illness was related to the occurrence of cardiovascular disease.
12. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360(3), 225-235 (2009).
13. Waterland RA, Travisano M, Tahiliani KG, Rached MT, Mirza S. Methyl donor supplementation prevents transgenerational amplification of obesity. Int. J. Obes. (Lond.) 32(9), 1373-1379 (2008).
14. Wang J, Wu Z, Li D et al. Nutrition, epigenetics, and metabolic syndrome. Antioxid. Redox Signal. doi:10.1089/ars.2011.4381 (2012) (Epub ahead of print).
15. Friso S, Choi SW, Girelli D et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl Acad. Sci. USA 99(8), 5606-5611 (2002).
16. Grundy S, Cleeman J, Daniels S et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit. Pathw. Cardiol. 4(4), 198-203 (2005).
17. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67(3), 255-262 (2010).
18. Orrell A, Doherty P, Miles J, Lewin R. Development and validation of a very brief questionnaire measure of physical activity in adults with coronary heart disease. Eur. J.Cardiovasc. Prev. Rehabil. 14(5), 615-623 (2007).
19. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19(19), 5444 (1991).
20. Marsh S, King CR, Garsa AA, McLeod HL. Pyrosequencing of clinically relevant polymorphisms. Methods Mol. Biol. 311, 97-114 (2005).
21. Pilsner JR, Hu H, Ettinger A et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ. Health Perspect. 117(9), 1466-1471 (2009).
22. Zhang FF, Cardarelli R, Carroll J et al. Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood. Epigenetics 6(5), 623-629 (2011). Examines gender-related differences in DNA methylation. The authors found that, in general, females had lower levels of DNA methylation.
23. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1), 19-32 (2005).
24. Roseboom TJ, Painter RC, van Abeelen AF, Veenendaal MV, de Rooij SR. Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas 70(2), 141-145 (2011). First study to examine methylation differences related to schizophrenia.
25. Dempster EL, Pidsley R, Schalkwyk LC et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 20(24), 4786-1496 (2011).
26. Bentley TG, Willett WC, Weinstein MC, Kuntz KM. Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am. J. Public Health 96(11), 2040-2047 (2006).
27. Ursini G, Bollati V, Fazio L et al. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. J. Neurosci. 31(18), 6692-6698 (2011).
28. Murphy BC, O'Reilly RL, Singh SM. Site-specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133B(1), 37-42 (2005).
29. Examining risk factors for atypical antipsychotic metabolic side effects. http://clinicaltrials.gov/ct2/show/NCT00815854
30. Pyrosequencing. www.pyrosequencing.com